Tag: Biovail

Canadian Drug Company Biovail Settles SEC Accounting Fraud Charges

Written by on Friday, March 28th, 2008

Canadian drug company Biovail Corporation has agreed to pay $10 million to settle federal regulators’ charges of civil accounting fraud and deceiving investors and analysts, reported Marcy Gordon for Associated Press.  SEC charges remain pending against Biovail’s founder and former chairman and CEO, Eugene Melnyk; former Chief Financial Officer Brian Crombie; and two current executives: Chief Financial Officer Kenneth Howling and Controller John Miszuk. The Ontario Securities Commission also has charges pending against the four executives.

Gordon reported on the charges as follows:

Biovail and senior executives "engaged in a pattern of systemic, chronic fraud" that distorted its quarterly and annual reports filed over four years, Mark Schonfeld, director of the SEC’s New York regional office, said in a statement. To conceal the fraud, the executives "intentionally misled the company’s auditors and the investing public, showing their complete disregard for their responsibilities to shareholders," Schonfeld said.

In October 2003, the SEC alleged, Biovail and several executives deceived investors and analysts by falsely attributing nearly half of the company’s failure to meet its third-quarter earnings target to a truck accident involving a shipment of Biovail’s antidepressant Wellbutrin XL. The accident in fact had no effect on earnings for the quarter, the SEC said.

The agency also accused the company of three fraudulent accounting schemes between 2001 and 2003: Shifting around $47 million in expenses for drug research and development onto the books of a "special purpose entity," concocting a phony transaction to record $8 million in revenue, and intentionally misstating losses from foreign currency transactions to understate a quarterly loss by some $3.9 million.

As part of the settlement, Biovail has agreed to refrain from future securities violations and to hire an independent accounting firm to oversee its books.

Attached is the SEC Press Release issued following the settlement agreement and the Complaint filed by the SEC in this case.

Category: Biotech Legal Disputes  |  Comments Off on Canadian Drug Company Biovail Settles SEC Accounting Fraud Charges

© 2008-2015 The Prinz Law Office. All rights reserved.

The Prinz Law Office | Silicon Valley, CA | Los Angeles, CA | Orange County, CA | San Diego, CA | Atlanta, GA | Tel: 1.800.884.2124

Mailing Address: 117 Bernal Rd., Suite 70-110, San Jose, CA 95119; Silicon Valley Office: San Jose- 2033 Gateway Place, Suite 500, San Jose, CA 95110 (408)884-2854; Los Angeles Office: 3110 Main St., Building C, Santa Monica, CA 90405 (310)907-9218; Orange County Office: 100 Spectrum Center Drive, 9th Floor, Irvine, CA 92618 (949)236-6777; San Diego Office: 4455 Murphy Canyon Road, Suite 100, San Diego, CA 92123 (619)354-2727 Atlanta Office: 1000 Parkwood Circle, Suite 900, Atlanta, Georgia 30339 (404)479-2470

Biotech Transactions Lawyer & Attorney: Serving Silicon Valley, San Jose, San Francisco, San Diego, Los Angeles, Orange County, Irvine, Anaheim, Santa Monica, Silicon Beach, Atlanta. Licensed in California and Georgia.